Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

n’s GAAP diluted EPS were $1.08 in the fourth quarter of 2010, an increase of 17 percent compared to $0.92 in the same quarter last year. GAAP net income of $1,022 million in the fourth quarter of 2010 increased 10 percent from $931 million in the fourth quarter of 2009.  For the full year 2010, Amgen’s reported GAAP EPS were $4.79, an increase of 6 percent compared to $4.51 for the full year 2009. For the full year 2010, GAAP net income increased slightly to $4,627 million versus $4,605 million for the full year 2009.  GAAP net income for the fourth quarter of 2010 was positively impacted by a favorable tax settlement as a result of settling certain non-routine transfer pricing issues aggregating $113 million, partially offset by an impairment charge associated with the Company’s recently announced transaction involving its manufacturing operation in Fremont, California aggregating $118 million on a pretax basis ($74 million after tax).

Product Sales PerformanceTotal product sales were $3,760 million in the fourth quarter of 2010 versus $3,743 million in the fourth quarter of 2009.  U.S. product sales were $2,869 million in the fourth quarter of 2010 versus $2,882 million in the fourth quarter of 2009. Fourth quarter 2010 U.S. product sales included a $65 million unfavorable impact due to U.S. health care reform. International product sales increased 3 percent to $891 million in the fourth quarter of 2010 versus $861 million in the fourth quarter of 2009.  Excluding the $26 million negative impact of foreign exchange in the fourth quarter of 2010, total product sales increased 1 percent and international product sales increased 7 percent.  For the year, total product sales increased 2 percent to $14,660 million in 2010 versus $14,351 million in 2009.  U.S. product sales increased 1 percent to $11,254 million in 2010 versus $11,135 million in the prior year.  For the year, U.S. product sales included a $
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the list ... the Zacks Equity Research analysts discuss the latest news ... recently featured in the blog include the Avanir Pharmaceuticals (Nasdaq: ... NPSP - Free Report ), Orexigen (Nasdaq: ... - Free Report ) and Gilead (Nasdaq: GILD ...
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
... AGAWAM, Mass., June 7, 2011 A free white ... validation of their cleaning processes is available from Microtest ... . As many medical devices are made ... plastics, manufacturers may require the use of various agents ...
... Biomedical Inc., a developer of an advanced implantable vena cava ...  The round was led by Three Arch Partners, which was ... Vena cava filters, which were first introduced ... that can lead to a potentially fatal pulmonary embolism (PE). ...
Cached Medicine Technology:New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes 2Crux Successfully Completes Funding for Advanced Filter for PE Prevention 2
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 "Medical ... patient care while also maintaining the patient's privacy," said ... up with this idea in order to supply caregivers ... well." , They created a prototype for The Helper ... device enables staff to turn patient onto his or ...
(Date:9/18/2014)... 2014 Companies in the Carbon ... selling it to downstream industries in either gas, liquid ... are food and beverage manufacturers. Food producers use carbon ... or pizzas. The gas is also used as a ... to carbonate soft drinks, beer and other beverages. According ...
(Date:9/18/2014)... Daily supplements of selenium or vitamin E don,t seem ... among men, a new study indicates. Previous animal ... prevent cataracts. To investigate this further, William Christen, from ... Boston, and his colleagues examined data from a randomized, ... was initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... Lambertville, NJ (PRWEB) September 18, 2014 ... consulting firm, announced today that President and co-founder ... Business Journal’s Innovation Award Winners for 2014, recognizing ... naming him as an emerging executive of the ... health care and life sciences that continue to ...
(Date:9/18/2014)... 18, 2014 Stealth Health Revolution ... advocate, and Frank Davis, founder of Food for ... are pleased to announce the new recipe book, ... delicious, nutrition-packed meals using Activz whole-food powders." ... step in the Stealth Health Revolution ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... ... scores to the Centers for Medicare and Medicaid Services , ... Houston, TX (PRWEB) October 6, 2009 -- ... beneficiaries in the counties of Harris, Fort Bend, Montgomery, and Galveston on the Mainland, ...
... , New National Survey Finds Jobless Individuals Four Times ... 6 A new national survey shows the economic downturn is ... who are unemployed are four times as likely as those with ... Americans who experienced involuntary changes in their employment status, such as ...
... Oct. 6 iJET Intelligent Risk Systems, a ... services, today announced the third webinar in its ... Resiliency." These interactive webinars help multinational organizations institute ... their organizations, especially amidst the ongoing effects of ...
... ... gathered recently at the Massachusetts Institute of Technology,s Faculty Club for ... being used to save lives, reduce suffering and extend human potential. ... by Alexander Medvedev, PhD., Vice President, Research & Development, Terumo Heart, ...
... bioTheranostics, a bioMerieux company that discovers, develops and commercializes ... company has signed a two-year agreement with Lab21 to ... in the United Kingdom (UK), Ireland and Middle East ... the terms of the agreement, UK-based Lab21 will market ...
... ... the parts washing industry. Midbrook has extensive experience washing parts and equipment in a variety ... facility to help a North American automotive parts supplier solve a de-rusting issue. , ... (Vocus) October 6, 2009 -- ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 3Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 2Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 3Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 2Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 3Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3
Inquire...
... The new GUCCI DONNA eyewear collection ... house,incorporating, with a vintage yet contemporary feel, ... leader., The new GUCCI UOMO optical and ... is,presented in classic lines with cutting-edge design ...
Inquire...
... art software package designed to assist in the ... a lens manufacturer with years of experience in ... designed to help you run your lab the ... software dictates., ,Designed specifically for integrated retail and ...
Medicine Products: